Position in DERM
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$174,443
-$47,126 QoQ
Shares Held
37,195
+29.4% QoQ
Ownership
0.132%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in DERM Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Bank of New York Mellon Corp holds $1,289,702,180 across 44 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
3,322,319 | $238,741,833 | |
| 2 | VTRS |
Viatris Inc
|
14,288,053 | $226,894,274 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
294,413 | $159,521,790 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
699,125 | $117,830,519 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
3,411,532 | $83,957,795 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,899,912 | $64,369,013 | |
| 7 | ALKS |
Alkermes plc.
|
1,097,282 | $57,497,573 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
441,831 | $49,016,724 |
All Filings in DERM
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $174,443 | 37,195 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $221,569 | 28,738 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $174,382 | 24,492 | Shares | Defined | 2025-11-03 | |
| 2025-06-30 | $178,536 | 24,866 | Shares | Defined | 2025-08-05 | |
| No filing history on record for this holder in this stock. | ||||||